Evidence map›Paper›PMID 41394978›Full record

ReviewFrontiers in bioengineering and biotechnology2025

Decoding the exosomal secretome: stem cell-elicted microenvironmental reprogramming for anterior cruciate ligament regenerative medicine.

Junjie Chen, Jiayang He, Dujiang Yang, Yuhan He, Yuhao Wei, Zhiqiang Zhang, Xue Zhou, Ming Cheng

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Stress Fracture in Athletes: A Practical Approach.Journal of clinical medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junjie Chen *Department of Rehabilitation, Jinniu District People's Hospital of Chengdu, Chengdu, China.
Jiayang He *Southwest Medical University, Luzhou, China.
Dujiang Yang *College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
Yuhan HeSouthwest Medical University, Luzhou, China.
Yuhao WeiSouthwest Medical University, Luzhou, China.
Zhiqiang ZhangDepartment of Rehabilitation, Jinniu District People's Hospital of Chengdu, Chengdu, China.
Xue ZhouDepartment of Rehabilitation, Jinniu District People's Hospital of Chengdu, Chengdu, China.
Ming ChengDepartment of Rehabilitation, Jinniu District People's Hospital of Chengdu, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ACL rupture is a prevalent and debilitating joint injury that has garnered significant clinical and scientific interest. Surgical reconstruction is often necessary for ACL rupture, yet numerous clinical cases indicate that the outcomes of such procedures are frequently suboptimal. Research has highlighted that the treatment of ACL rupture is particularly challenging due to factors such as the inflammatory response, the formation of vascular scar tissue, and the slow healing of tendon-bone interface attachment points. These complications result in poor integration of tendon grafts within bone tunnels. Recent advancements in stem cell research have introduced new possibilities for ACL rupture treatment. However, stem cell therapy is not without its limitations, including safety concerns such as the risk of aberrant differentiation leading to oncogenesis. Exosomes, a type of extracellular vesicle secreted by stem cells, have been found to modulate immune responses, promote neovascularization, influence scar formation, and regulate bone homeostasis

Indexed as

ACL rupturebone homeostasisexosomesinflammatory responseneovascularizationstem cell therapy

Identifiers

PMID41394978
PMCPMC12698602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.